Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02643667
Recruitment Status :
(The study closed at UCSF and the study moved to Washington University. Waiting on IRB approval at Washington University.)
30-40% of patients who undergo radical prostatetecomy (RP) with curative intent for their localized prostate cancer experience relapse of their disease. Thus, improved therapeutic approaches are needed in this patient population. Enhancing the patient's anti-tumor immune response prior to surgery may improve long-term outcomes following RP.
Condition or disease
Drug: IbrutinibProcedure: Blood samples for PSA and immune assaysProcedure: Radical prostatectomy
Dose Limiting Toxicities (Phase 1) [ Time Frame: Completion of enrollment of Phase I portion of patients ]
DLTs will be defined as any of the following that are attributable to ibrutinib.
Any grade 4 toxicity, including hematologic toxicities with the exception of lymphocytosis. Lymphocytosis, in the absence of clinical symptoms, is excluded from DLT, as this may be considered an on-target pharmacodynamics effect of BTK inhibition.
Any grade 3 toxicity.
Any recurrence of the same grade 3 toxicity.
Any delay of RP due to study-drug related toxicity.
Any complications of RP (e.g., bleeding, delayed wound healing) deemed to be related to study drug.
B cell infiltration (Phase 2) [ Time Frame: Completion of follow-up (approximately 10 weeks after start of treatment) ]
T cell infiltration (Phase 2) [ Time Frame: Completion of follow-up (approximately 10 weeks after start of treatment) ]
Secondary Outcome Measures :
Dose-dependent change in B cell infiltration (Phase 1) [ Time Frame: Completion of follow-up (approximately 10 weeks after start of treatment) ]
Dose-dependent change in T cell infiltration (Phase 1) [ Time Frame: Completion of follow-up (approximately 10 weeks after start of treatment) ]
Dose-dependent change in circulating B cells (Phase 1) [ Time Frame: Completion of follow-up (approximately 10 weeks after start of treatment) ]
Dose-dependent change in circulating T cells (Phase 1) [ Time Frame: Completion of follow-up (approximately 10 weeks after start of treatment) ]
Change in frequency of circulating B cells (Phase 2) [ Time Frame: Completion of follow-up (approximately 10 weeks after start of treatment) ]
Change in frequency of circulating T cells (Phase 2) [ Time Frame: Completion of follow-up (approximately 10 weeks after start of treatment) ]
Cytotoxic effect (Phase 2) [ Time Frame: Completion of follow-up (approximately 10 weeks after start of treatment) ]
Laboratory evaluations (>/= 50% PSA decline)
Treatment response [ Time Frame: Completion of follow-up (approximately 10 weeks after start of treatment) ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
18 years of age or older
ECOG performance status 0 or 1
Histologically documented adenocarcinoma of the prostate
Patients must be suitable for and willing to undergo a radical prostatectomy at the completion of study therapy.
Adequate bone marrow function, defined as:
WBC >2,500 cells/mm3
ANC >1,500 cells/mm3
Hemoglobin >9 mg/dL
Platelet count >100,000 cells/mm3
Adequate renal function, defined as serum creatinine <2 mg/dL or CrCl >30 mL/min
Adequate liver function, defined as:
AST and ALT <2.5x institutional ULN
Serum bilirubin <1.5x institutional ULN
Adequate coagulation function, defined as normal PT/INR and PTT
Ability to understand and willingness to sign a written informed consent document
Available evaluable archival tumor tissue for correlative studies including assessment of immune infiltration and Btk expression is required. If archival tissue is unavailable, patients must be willing to undergo repeat prostate biopsy. Tissue is considered sufficient for correlative endpoint analyses if they are obtained from at least 2 prostate cores and consist of at least 15 unstained slides from the largest tumor volume and/or highest Gleason score. The availability of archival tissue or consent for repeat prostate biopsy is required for study eligibility; determination of tissue sufficiency is not required for study eligibility.
The effects of ibrutinib on the developing human fetus is unknown. Men treated or enrolled on this protocol must agree to use adequate contraception prior to the study, for the duration of the study participation, and for 3 months after completion of treatment.
Patients with neuroendocrine or small cell features are not eligible.
Any evidence of metastatic disease. Pre-operative staging will be undertaken per urologic standard of care.
Any prior use of hormonal therapy, including:
GNRH agonists or GNRH antagonists (e.g., leuprorelin, degarelix)
PC-SPES or PC-x products. Other herbal therapies or supplements will be considered by the Principle Investigator on a case by case basis based on their potential for hormonal or anti-cancer therapies.
Chemotherapy ≤ 21 days prior to first administration of study treatment and/or monoclonal antibody ≤ 6 weeks prior to first administration of study treatment
Prior radiation therapy for prostate cancer
Prior exposure to BTK inhibitors
Prior investigational therapy for prostate cancer
Patients may not receive any other concurrent investigational agents while on study.
Use of systemic steroid therapy within 28 days of study screening. Patients on inhaled or topical steroids are eligible.
Concurrent systemic immunosuppressive therapy within 21 days of the first dose of study drug.
Major surgery requiring the use of general anesthetic within 4 weeks of study enrollment
HIV, active hepatitis B (HBV) or active hepatitis C (HCV)
Patients with past HBV infection or resolved HBV infection, defined as the presence of hepatitis B core antibody (HBc Ab) and absence of hepatitis B surface antigen (HBsAg) are eligible. HBV DNA must be obtained in these patients prior to day 1 of ibrutinib therapy, but detection of HBV DNA in these patients will not exclude study participation.
Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
Inability to swallow capsules or presence of malabsorption syndromes, disease significantly affecting gastrointestinal function, history of resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete small obstruction.
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Function Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to screening.
Uncontrolled concurrent illness, or any underlying medical condition, which in the Principal Investigator's opinion will make the administration of ibrutinib hazardous or obscure the interpretation of adverse events.
Recent infection requiring systemic treatment that was completed within 14 days prior to the first dose of study drug
Concurrent active malignancy other than non-melanoma skin cancers. Patients are considered to be free of active malignancy if they have completed curative therapy and have a <30% risk of relapse.
Moderate or severe hepatic impairment defined as Child-Pugh Class B or C.
History of congenital bleeding diathesis.
Known bleeding disorders (e.g. von Willebrand's disease or hemophilia).
Concomitant use of anticoagulants including warfarin, other Vitamin K antagonists, and enoxaparin.
Subjects who received a strong or moderate cytochrome P450 (CYP) 3A4 inhibitor within 7 days prior to the first dose of ibrutinib or patients who require treatment with a strong or moderate cytochrome P450 (CYP) 3A inhibitor.
Vaccination with live, attenuated vaccines within 4 weeks of first dose of study drug.
Major surgery within 4 weeks of the first dose of study drug.
Patients on anti-platelet agents including clopidogrel and glycoprotein IIb/IIIa inhibitors. Aspirin is allowed, but should be held before surgery according to standard practices.
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child-Pugh classification
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.
Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to CTCAE v 4.03 grade 0 or 1 or to the levels dictated in the eligibility criteria with the exception of alopecia.